Company intelligence / Profile preview
Hofseth BioCare ASA
- Ownership
- Private
- Development stage
- Other
Overview
Hofseth BioCare has demonstrated in exploratory human studies that its OmeGo® whole salmon oil provides broad inflammation-resolving effects and improved interferon response. ProGo® has shown improved iron metabolism in humans. Larger clinical trials are ongoing or planned for respiratory health benefits of OmeGo®. The company’s biotech spinout HBC Immunology has a lead program in prostate cancer entering the clinic.
- Therapeutic areas
- OtherPulmonologyGastroenterologyHematology
- Modalities
- Bioactive peptides (from salmon protein hydrolysate)Marine-derived oils (whole salmon oil)Collagen and mineral complexes (from salmon bone)Peptide fractions as medical food
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Hofseth BioCare ASA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hofseth BioCare ASA.